NRP1 and neoplasm: Indeed, several works have proposed a tumour suppressive role for SEMA3A, which has been reported to restrain tumour growth by hampering tumour angiogenesis.59 In PDAC, an NRP1-independent superagonist SEMA3A was used as vasculature normalising agent which demonstrated antitumour activity.60 Moreover, there are contradictory results on the effect of SEMA3A on recruitment and activation of TAMs.